Innovations in Genetics Microgravity

Share this:
Published: 9 Mar 2018

This edition of the Genetic Technology TOE depicts trends across genetics microgravity research. Microgravity is a disruptive opportunity for various segments of the healthcare sector, including pharmaceuticals, biotechnology, nutrition, and material sciences. Genetics microgravity research provides companies and researchers the ability to accelerate discovery processes for new drugs and vaccines, and to develop new crystals and materials, thereby accelerating human genome and origin of diseases understanding. The potential scientific, technological, and commercial benefits of genetics microgravity research are significant, and they are expected to revolutionize traditional processing methods. The corresponding clinical trials scenario is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Genetics microgravity, genes in space, remote controlled labs, polymerase chain reaction, PCR, DNA sequence, next generation sequencing, gene editing, International Space Station, ISS, stem cells


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..